Literature DB >> 6763626

Plasma protein binding of furosemide in kidney transplant patients.

D E Smith, L Z Benet.   

Abstract

The present investigation was undertaken in order to determine the in vivo plasma protein binding of furosemide in kidney transplant patients and its possible consequence on furosemide effect. Using an equilibrium dialysis technique, serial plasma samples of furosemide taken after intravenous administration were dialyzed against an equal volume of isotonic Krebs Ringer bicarbonate buffer (pH 7.4). Dialysis was performed at 37 degrees C for 5 hr, and furosemide concentrations (total as well as free) were analyzed by HPLC using fluorescence detection. It was observed that kidney transplant patients on concomitant sulfisoxazole treatment (KT+) had a significantly greater value for percent free of furosemide as compared to transplant patients not on sulfisoxazole (KT-) (4.4 +/- 0.8 for KT+ vs. 1.7 +/- 0.3% for KT-; p less than 0.01) as well as to healthy volunteers (4.4 +/- 0.8 for KT+ vs. 1.2 +/- 0.2% for controls; p less than 0.01). In addition, kidney transplant patients not on concomitant sulfisoxazole treatment had a significantly higher value for percent free of furosemide with respect to healthy volunteers (p less than 0.05). Nonlinear plasma protein binding was also observed for one patient, who had values for percent free of furosemide ranging from 1.3 to 12.9%. However, no significant correlation was found between the fraction of the dose excreted unchanged in the urine and percent free of furosemide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6763626     DOI: 10.1007/bf01062547

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  23 in total

1.  Tubular chloride transport and the mode of action of some diuretics.

Authors:  M B Burg
Journal:  Kidney Int       Date:  1976-02       Impact factor: 10.612

2.  Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension.

Authors:  F Andreasen; O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

3.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

4.  Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.

Authors:  F Andreasen; P Jakobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-07

5.  Pharmacokinetics of furosemide in advanced renal failure.

Authors:  C M Huang; A J Atkinson; M Levin; N W Levin; A Quintanilla
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

6.  Furosemide effect on isolated perfused tubules.

Authors:  M Burg; L Stoner; J Cardinal; N Green
Journal:  Am J Physiol       Date:  1973-07

7.  Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.

Authors:  R E Cutler; A W Forrey; T G Christopher; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

8.  Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans.

Authors:  T N Tozer; J G Gambertoglio; D E Furst; D S Avery; N H Holford
Journal:  J Pharm Sci       Date:  1983-12       Impact factor: 3.534

Review 9.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Furosemide kinetics in renal failure.

Authors:  W J Tilstone; A Fine
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

View more
  5 in total

Review 1.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  Renal transport kinetics of furosemide in the isolated perfused rat kidney.

Authors:  L J Lee; J A Cook; D E Smith
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

Review 3.  Pharmacokinetic changes in patients with oedema.

Authors:  B Vrhovac; N Sarapa; I Bakran; M Huic; V Macolic-Sarinic; I Francetic; A Wolf-Coporda; F Plavsic
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

4.  Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition.

Authors:  S H Kim; Y M Choi; M G Lee
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

Review 5.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.